Multicenter , multinational , randomized , double-blind , placebo-controlled studies have been designed to evaluate efficacy and safety of alirocumab in more than @ patients with heFH who are not adequately controlled with a maximally-tolerated stable daily dose of statin for @weeks prior to the screening visit , with or without other lipid-lowering therapy .